H
Herophilus
Neurotherapeutics company leveraging phenotypic screening, human brain models, and machine learning to develop novel drugs for neurological diseases
About Herophilus
Herophilus is a San Francisco-based neurotherapeutics company focused on discovering novel drugs for complex neurological and psychiatric diseases. The company employs phenotypic screening, which involves observing the physical and biochemical characteristics of cells and tissues, to identify potential drug candidates. Herophilus combines human brain models, scaled biology, and machine learning to decode brain diseases from genetics to neural computation. This approach allows the company to gain deep biological insights and systematically develop drugs with greater therapeutic potential.
Herophilus serves clients in the pharmaceutical and biotechnology sectors, particularly those focused on neurological and psychiatric conditions. The company operates in the neurotherapeutics market, which aims to address the unmet medical needs of patients with brain diseases. Herophilus' business model revolves around drug discovery and development, partnering with other companies for clinical trials and commercialization. Revenue is generated through licensing agreements, research collaborations, and milestone payments.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
KF Ventures
Luxor Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Herophilus on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Herophilus on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.